Comerica Bank Has $2.18 Million Stock Position in Enovis Co. (NYSE:ENOV)

Comerica Bank increased its position in shares of Enovis Co. (NYSE:ENOV - Free Report) by 22.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 49,560 shares of the company's stock after purchasing an additional 9,224 shares during the quarter. Comerica Bank owned 0.09% of Enovis worth $2,175,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of Enovis by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 5,486,130 shares of the company's stock worth $240,731,000 after buying an additional 75,348 shares during the last quarter. DAVENPORT & Co LLC lifted its holdings in shares of Enovis by 6.0% in the fourth quarter. DAVENPORT & Co LLC now owns 2,782,341 shares of the company's stock worth $121,181,000 after acquiring an additional 157,216 shares during the last quarter. Royce & Associates LP boosted its stake in shares of Enovis by 2.8% in the 4th quarter. Royce & Associates LP now owns 2,470,576 shares of the company's stock valued at $108,409,000 after purchasing an additional 66,891 shares in the last quarter. River Road Asset Management LLC grew its holdings in shares of Enovis by 3.8% during the 4th quarter. River Road Asset Management LLC now owns 1,238,357 shares of the company's stock valued at $54,339,000 after purchasing an additional 45,762 shares during the last quarter. Finally, Boston Partners increased its position in Enovis by 27.1% during the 4th quarter. Boston Partners now owns 1,048,532 shares of the company's stock worth $46,034,000 after purchasing an additional 223,816 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Trading Down 0.1 %

NYSE ENOV traded down $0.03 on Friday, hitting $33.05. The company's stock had a trading volume of 1,748,093 shares, compared to its average volume of 768,536. The company's 50-day moving average is $35.20 and its 200 day moving average is $41.57. The firm has a market cap of $1.89 billion, a PE ratio of -15.09 and a beta of 1.79. Enovis Co. has a 1-year low of $29.32 and a 1-year high of $53.84. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40.

Enovis (NYSE:ENOV - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.07. The business had revenue of $558.83 million during the quarter, compared to analyst estimates of $558.80 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. Enovis's revenue for the quarter was up 8.2% compared to the same quarter last year. During the same period last year, the company earned $0.50 EPS. As a group, analysts predict that Enovis Co. will post 2.79 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have weighed in on ENOV shares. Needham & Company LLC cut their target price on shares of Enovis from $64.00 to $57.00 and set a "buy" rating on the stock in a research report on Friday. JMP Securities reduced their price objective on Enovis from $62.00 to $55.00 and set a "market outperform" rating on the stock in a research report on Friday.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.